Newland Pharmaceutical Co., Ltd. (SHE:301277)
China flag China · Delayed Price · Currency is CNY
14.03
-0.19 (-1.34%)
Last updated: Jun 26, 2025

Newland Pharmaceutical Ratios and Metrics

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2018 - 2019
Period Ending
Jun '25 Dec '24 Dec '23 Jan '23 Jan '22 Dec '20 2018 - 2019
5,4933,8734,1633,850--
Upgrade
Market Cap Growth
25.84%-6.96%8.12%---
Upgrade
Enterprise Value
4,7113,0723,3783,956--
Upgrade
Last Close Price
14.019.6410.199.28--
Upgrade
PE Ratio
31.6122.3126.1929.10--
Upgrade
PS Ratio
7.215.336.396.14--
Upgrade
PB Ratio
3.432.512.872.83--
Upgrade
P/TBV Ratio
3.512.572.952.92--
Upgrade
P/FCF Ratio
-242.5025.55452.81--
Upgrade
P/OCF Ratio
40.9730.5616.0446.47--
Upgrade
EV/Sales Ratio
6.194.235.196.31--
Upgrade
EV/EBITDA Ratio
21.0514.2217.7223.63--
Upgrade
EV/EBIT Ratio
25.5116.9820.8727.22--
Upgrade
EV/FCF Ratio
-1354.46192.3320.73465.21--
Upgrade
Debt / Equity Ratio
0.000.000.000.000.310.35
Upgrade
Debt / EBITDA Ratio
0.020.010.010.030.800.69
Upgrade
Debt / FCF Ratio
-0.190.020.675.343.57
Upgrade
Asset Turnover
0.430.420.410.570.860.90
Upgrade
Inventory Turnover
14.1811.509.306.124.815.81
Upgrade
Quick Ratio
5.905.267.897.141.421.22
Upgrade
Current Ratio
6.125.518.297.611.821.51
Upgrade
Return on Equity (ROE)
11.21%11.56%11.19%14.92%31.91%46.93%
Upgrade
Return on Assets (ROA)
6.46%6.61%6.44%8.25%14.32%18.59%
Upgrade
Return on Capital (ROIC)
7.41%7.54%7.18%9.57%17.82%26.01%
Upgrade
Return on Capital Employed (ROCE)
11.10%11.30%11.00%10.50%30.50%41.50%
Upgrade
Earnings Yield
3.17%4.48%3.82%3.44%--
Upgrade
FCF Yield
-0.06%0.41%3.91%0.22%--
Upgrade
Dividend Yield
2.04%2.96%2.00%1.83%--
Upgrade
Payout Ratio
45.91%46.08%41.94%5.12%31.92%45.98%
Upgrade
Buyback Yield / Dilution
-1.13%-0.39%-29.52%-2.59%-0.64%-0.34%
Upgrade
Total Shareholder Return
0.88%2.57%-27.51%-0.75%-0.64%-0.34%
Upgrade
Updated Mar 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.